Friday, July 31, 2015

Pfizer gets $2.15 billion from Teva and Sun Pharma in patent settlement

Pfizer said Wednesday morning that Teva will pay it $1.6 billion and Sun Pharma will pay it $550 million to settle a patent lawsuit over the stomach acid medicine, Protonix.

Pfizer gets $2.15 billion from Teva and Sun Pharma in patent settlement

0 comments
Taking a risk, Teva launched its generic version of the stomach acid reducing drug Protonix in December 2007 while challenging the patent of Nycomed that had been licensed to Wyeth. Pfizer bought Wyeth in 2009 and inherited the litigation.
Taking a risk, Teva launched its generic version of the stomach acid reducing drug Protonix in December 2007 while challenging the patent of Nycomed that had been licensed to Wyeth. Pfizer bought Wyeth in 2009 and inherited the litigation.

Pfizer said Wednesday morning that Teva will pay it $1.6 billion and Sun Pharma will pay it $550 million to settle a patent lawsuit over the heartburn medicine Protonix.

The companies were in the midst of the damages phase of a jury trial in federal court in Newark, N.J. A separate jury had found in favor of Pfizer in 2010.

An Inquirer story from June 2, advancing the damages phase, is here.

The corporate history of this also includes licensing and mergers. Takeda Pharmaceuticals had inherited ownership of the patent, but previously it was licensed to Wyeth. Wyeth was then bought by Pfizer. Through all of that, Takeda shares the money with Pfizer, with Pfizer getting 64 percent or about $1.38 billion.

"As part of the settlement, both Teva and Sun have admitted that their sales of generic pantoprazole infringed the patent that was held valid by the court," Pfizer said in its statement.

“We are pleased with today's settlement, which recognizes the validity and value of the innovation that led to Protonix,” Amy W. Schulman, executive vice president and general counsel of Pfizer, said in a statement. “Protecting intellectual property is vital as we develop new medicines that save and enhance patients’ lives.”

Teva will pay $800 million in 2013 and the remaining $800 million by October 2014. Sun will pay all of its share in 2013.

“We are pleased to put this matter behind us as we continue to focus on delivering safe and affordable medicines to patients around the world,” Richard Egosi, Teva's Executive Vice President and Chief Legal Officer, said in a statement.

 

 

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
letter icon Newsletter